Predicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel disease
Monoclonal antibodies to tumor necrosis factor (TNF) have become a mainstay of the
therapeutic armamentarium in inflammatory bowel disease (IBD) over the last 15 years …
therapeutic armamentarium in inflammatory bowel disease (IBD) over the last 15 years …
Predicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel disease
U Kopylov, E Seidman - Therapeutic Advances in Gastroenterology, 2016 - cir.nii.ac.jp
抄録< jats: p> Monoclonal antibodies to tumor necrosis factor (TNF) have become a
mainstay of the therapeutic armamentarium in inflammatory bowel disease (IBD) over the …
mainstay of the therapeutic armamentarium in inflammatory bowel disease (IBD) over the …
Predicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel disease
U Kopylov, E Seidman - Therapeutic advances in …, 2016 - pubmed.ncbi.nlm.nih.gov
Monoclonal antibodies to tumor necrosis factor (TNF) have become a mainstay of the
therapeutic armamentarium in inflammatory bowel disease (IBD) over the last 15 years …
therapeutic armamentarium in inflammatory bowel disease (IBD) over the last 15 years …
[HTML][HTML] Predicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel disease
U Kopylov, E Seidman - Therapeutic Advances in …, 2016 - ncbi.nlm.nih.gov
Monoclonal antibodies to tumor necrosis factor (TNF) have become a mainstay of the
therapeutic armamentarium in inflammatory bowel disease (IBD) over the last 15 years …
therapeutic armamentarium in inflammatory bowel disease (IBD) over the last 15 years …
Predicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel disease.
U Kopylov, E Seidman - Therapeutic Advances in Gastroenterology, 2016 - europepmc.org
Monoclonal antibodies to tumor necrosis factor (TNF) have become a mainstay of the
therapeutic armamentarium in inflammatory bowel disease (IBD) over the last 15 years …
therapeutic armamentarium in inflammatory bowel disease (IBD) over the last 15 years …
Predicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel disease.
U Kopylov, E Seidman - Therapeutic Advances in …, 2016 - search.ebscohost.com
Monoclonal antibodies to tumor necrosis factor (TNF) have become a mainstay of the
therapeutic armamentarium in inflammatory bowel disease (IBD) over the last 15 years …
therapeutic armamentarium in inflammatory bowel disease (IBD) over the last 15 years …
Predicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel disease.
U Kopylov, E Seidman - Therapeutic Advances in Gastroenterology, 2016 - europepmc.org
Monoclonal antibodies to tumor necrosis factor (TNF) have become a mainstay of the
therapeutic armamentarium in inflammatory bowel disease (IBD) over the last 15 years …
therapeutic armamentarium in inflammatory bowel disease (IBD) over the last 15 years …